Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 11/20 | 0.78 |
| ▸ | FGFR1 | P11362 | 11/20 | 0.78 |
| ▸ | BLK | P51451 | 11/20 | 0.78 |
| ▸ | STK3 | Q13188 | 11/20 | 0.78 |
| ▸ | ROCK1 | Q13464 | 11/20 | 0.78 |
| ▸ | CSF1R | P07333 | 11/20 | 0.78 |
| ▸ | LCK | P06239 | 10/20 | 0.78 |
| ▸ | FLT1 | P17948 | 10/20 | 0.78 |
| ▸ | TAOK1 | Q7L7X3 | 10/20 | 0.78 |
| ▸ | FYN | P06241 | 10/20 | 0.78 |
| ▸ | MET | P08581 | 10/20 | 0.78 |
| ▸ | ROCK2 | O75116 | 10/20 | 0.78 |
| ▸ | LYN | P07948 | 10/20 | 0.78 |
| ▸ | NEK2 | P51955 | 10/20 | 0.78 |
| ▸ | MAP4K4 | O95819 | 9/20 | 0.78 |
| ▸ | MAP4K2 | Q12851 | 9/20 | 0.78 |
| ▸ | MARK2 | Q7KZI7 | 9/20 | 0.78 |
| ▸ | KIT | P10721 | 9/20 | 0.78 |
| ▸ | RPS6KB1 | P23443 | 9/20 | 0.78 |
| ▸ | AXL | P30530 | 8/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14633521 | 0.90 | AURKA (0.77) | AURKAFGFR1BLKSTK3ROCK1 | |
| SCHEMBL3528491 | 0.89 | KDR (0.83) | AURKAFGFR1BLKSTK3ROCK1 | |
| SCHEMBL17165797 | 0.88 | KDR (0.75) | AURKAFGFR1BLKSTK3ROCK1 | |
| SCHEMBL14633305 | 0.88 | KDR (0.75) | AURKAFGFR1BLKSTK3ROCK1 | |
| SCHEMBL27661139 | 0.87 | KDR (0.64) | AURKAFGFR1BLKSTK3ROCK1 | |
| SCHEMBL3535351 | 0.87 | KDR (0.83) | AURKAFGFR1BLKSTK3ROCK1 | |
| SCHEMBL14651409 | 0.86 | AURKA (0.77) | AURKAFGFR1BLKSTK3ROCK1 | |
| SCHEMBL3527777 | 0.86 | KDR (0.82) | AURKAFGFR1BLKSTK3ROCK1 | |
| SCHEMBL3527572 | 0.84 | KDR (0.81) | AURKAFGFR1BLKSTK3ROCK1 | |
| SCHEMBL3528124 | 0.84 | KDR (1.00) | AURKAFGFR1BLKSTK3ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2740458-B1 | Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide | IP GES FÜR MAN MBH (DE) | 2016-08-03 | — | — | EP | disclosed |
| EP-2740458-A1 | Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide | IP Gesellschaft für Management mbH (DE) | 2014-06-11 | — | — | EP | disclosed |
| US-8436179-B2 | Kinase inhibitor with improved solubility profile | ABBVIE INC. (US) | 2013-05-07 | — | — | US | disclosed |
| WO-2013012909-A1 | KINASE INHIBITOR WITH IMPROVED AQUEOUS SOLUBILITY | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013012909-A1 | KINASE INHIBITOR WITH IMPROVED AQUEOUS SOLUBILITY | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20130023555-A1 | KINASE INHIBITOR WITH IMPROVED SOLUBILITY PROFILE | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| US-20130023555-A1 | KINASE INHIBITOR WITH IMPROVED SOLUBILITY PROFILE | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023555-A1 | KINASE INHIBITOR WITH IMPROVED SOLUBILITY PROFILE | AURKC, AURKA, FLT4 | AURKA 2/4885FGFR1 93/4885BLK 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.